News

GRID VIEW

No more posts



Welcome to MedEvidence: Two Docs Talk Allergies and Asthma Part 3, Prevention, The Evil Eosinophils. In this episode, Dr. Michael Koren and Dr. Sunil Joshi explore allergy shots vs. allergy drops for managing allergic rhinitis. For people with allergic rhinitis, allergy shots, and drops are two treatment options. The doctors explain the difference between the two treatments and their effectiveness in reducing allergic rhinitis symptoms. They also discuss the pros and cons of each option and how to decide which one is best for you.

This series is the perfect resource for learning about allergies and asthma. Tune in to gain a deeper understanding of these important healthcare topics.

Common medications:

  • The anti-IL5 products that affect eosinophil survival are mepolizumab (Nucala), benralizumab (Fasenra), reslizumab (Cinqair).
  • The anti-IL4/IL13 product is dupilumab (Dupixent)
  • The anti-IgE agent is omalizumab (Xolair)
  • The anti-TSLP agent is Tezepelumab. (Teszpire)

Sunil Joshi, MD, is the President and Managing Partner of Family Allergy Asthma Consultants in Jacksonville, Florida. The Past-President of the Duval County Medical Society (the largest and oldest Medical Society in Florida) and a graduate for the University of Florida College of Medicine. Dr. Joshi received his Allergy/Immunology fellowship training at the University of Rochester in New York.  He truly enjoys treating patients with allergic disorders and believes that education about these disease processes can bring better care to the public.

Michael J. Koren, MD, is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research, which conducts clinical trials at 7 locations in Florida. He received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine and fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.

He is a fellow of the American College of Cardiology, fellow and two-time president of the Academy of Physicians in Clinical Research, and the regional chapter of the American Heart Association.


Prefer to listen to the podcast without video? You can do that below!








Welcome to MedEvidence: Two Docs Talk Allergies and Asthma Part 2, Prevention, Testing, and Treatment.  In this episode, Dr. Michael Koren and Dr. Sunil Joshi explore the importance of prevention before treatment and the different testing and treatment options available for pollen allergies. They also cover clinical treatments, such as immunotherapy, and how they can help manage symptoms.

This series is the perfect resource for learning about allergies and asthma. Tune in to gain a deeper understanding of these important healthcare topics.

Common medications:

  • The anti-IL5 products that affect eosinophil survival are mepolizumab (Nucala), benralizumab (Fasenra), reslizumab (Cinqair).
  • The anti-IL4/IL13 product is dupilumab (Dupixent)
  • The anti-IgE agent is omalizumab (Xolair)
  • The anti-TSLP agent is Tezepelumab. (Teszpire)

Sunil Joshi, MD, is the President and Managing Partner of Family Allergy Asthma Consultants in Jacksonville, Florida. The Past-President of the Duval County Medical Society (the largest and oldest Medical Society in Florida) and a graduate for the University of Florida College of Medicine. Dr. Joshi received his Allergy/Immunology fellowship training at the University of Rochester in New York.  He truly enjoys treating patients with allergic disorders and believes that education about these disease processes can bring better care to the public.

Michael J. Koren, MD, is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research, which conducts clinical trials at 7 locations in Florida. He received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine and fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.

He is a fellow of the American College of Cardiology, fellow and two-time president of the Academy of Physicians in Clinical Research, and the regional chapter of the American Heart Association.


Prefer to listen to the podcast without video? You can do that below!








Welcome to MedEvidence: Two Docs Talk Allergies and Asthma. In this part 4 series, Dr. Michael Koren and Dr. Sunil Joshi bring expert insights and valuable knowledge on allergies and asthma. Today’s Part 1- Pollen Season and Symptoms Associated with Pollen Allergies: As pollen season approaches, many people experience a range of symptoms associated with pollen allergies. The doctors discuss the common symptoms of pollen allergies, such as itchy eyes, runny nose, and congestion. They also cover the types of pollen that cause allergies and ways to avoid exposure.

This series is the perfect resource for learning about allergies and asthma. Tune in to gain a deeper understanding of these important healthcare topics.

Common medications:

  • The anti-IL5 products that affect eosinophil survival are mepolizumab (Nucala), benralizumab (Fasenra), reslizumab (Cinqair).
  • The anti-IL4/IL13 product is dupilumab (Dupixent)
  • The anti-IgE agent is omalizumab (Xolair)
  • The anti-TSLP agent is Tezepelumab. (Teszpire)

Sunil Joshi, MD, is the President and Managing Partner of Family Allergy Asthma Consultants in Jacksonville, Florida. The Past-President of the Duval County Medical Society (the largest and oldest Medical Society in Florida) and a graduate for the University of Florida College of Medicine. Dr. Joshi received his Allergy/Immunology fellowship training at the University of Rochester in New York.  He truly enjoys treating patients with allergic disorders and believes that education about these disease processes can bring better care to the public.

Michael J. Koren, MD, is a practicing cardiologist and Chief Executive Officer at Jacksonville Center for Clinical Research, which conducts clinical trials at 7 locations in Florida. He received his medical degree cum laude at Harvard Medical School and completed his residency in internal medicine and fellowship in cardiology at New York Hospital/Memorial Sloan-Kettering Cancer Center/Cornell Medical Center.

He is a fellow of the American College of Cardiology, fellow and two-time president of the Academy of Physicians in Clinical Research, and the regional chapter of the American Heart Association.


Prefer to listen to the podcast without video? You can do that below!





Encore logo

As a proven clinical research organization, we take every precaution to ensure the safety of and maximize the value for our research volunteers. Qualified doctors, nurses and study coordinators on staff provide support and care throughout the research trial. Participation is always voluntary. We appreciate the time and effort that research volunteers bring to this important process.

Copyright 2023 ENCORE Research Group